Skip to main content

Table 4 Comparison of complications between the PF-ILD and non-PF-ILD groups among patients with fibrosing ILD

From: Progressive fibrosing interstitial lung disease: prevalence and clinical outcome

  Total PF-ILD Non-PF-ILD P-value
Number of patients 396 135 261  
Follow-up duration, months 68.9 ± 32.5 59.9 ± 28.4 73.5 ± 33.5  < 0.001
Unexpected respiratory hospitalisation 120 (30.3) 62 (45.9) 58 (22.2)  < 0.001
Acute exacerbationa 74 (18.7) 38 (28.1) 36 (13.8) 0.001
 Time interval from diagnosis (months) 34.6 ± 28.2 29.3 ± 20.5 40.2 ± 33.9 0.037
Pneumonia 35 (8.8) 16 (11.9) 19 (7.3) 0.138
Pneumothorax 7 (1.8) 5 (3.7) 2 (0.8) 0.048
Pulmonary hypertension 89 (22.5) 45 (33.3) 44 (16.9)  < 0.001
Lung cancer 28 (7.1) 14 (10.4) 14 (5.4) 0.065
  1. Data are expressed as mean ± standard deviation or number (%) unless otherwise indicated
  2. aAcute worsening or development of dyspnea < 1 month in duration; new bilateral ground-glass opacity and/or consolidation superimposed on fibrosis; not fully explained by cardiac failure or volume overload
  3. PF progressive fibrosing, ILD interstitial lung disease